Overview
Diabetes Mellitus: Prevention strategies, predictors, treatment effects; kidney and other complications including cardiovascular outcomes. Utilization of EHR data to construct tools to improve the care of diabetes and comorbid conditions.
Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Endocrinology, Metabolism, and Nutrition,
Medicine
Member in the Duke Clinical Research Institute
·
2008 - Present
Duke Clinical Research Institute,
Institutes and Centers
Recent Publications
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
Journal Article J Am Soc Nephrol · April 1, 2026 KEY POINTS: We assessed whether baseline urine albumin-creatinine ratio (UACR) and eGFR modify treatment effects on UACR reduction and safety in the CONFIDENCE trial. Higher baseline eGFR or UACR, age, female sex, and atherosclerotic cardiovascular disease ... Full text Link to item CiteFat, muscle, and anti-obesity medications in cardiovascular disease prevention.
Journal Article Eur Heart J · March 31, 2026 The rapid expansion of anti-obesity treatments with glucagon-like peptide-1 receptor agonists has redefined weight management. A consistent component of this weight loss, however, involves not only fat mass but also lean body mass, including skeletal muscl ... Full text Link to item CiteAcute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
Journal Article J Am Soc Nephrol · March 29, 2026 KEY POINTS: We investigated the effect of empagliflozin, finerenone, and their combination on eGFR decline in people with type 2 diabetes and albuminuria. Acute declines in eGFR occurred more in those on combination therapy, on diuretics, and with higher e ... Full text Link to item CiteRecent Grants
GentiBio_GNTI-122-T1D-1001
Clinical TrialPrincipal Investigator · Awarded by GentiBio, Inc. · 2025 - 2035A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes
Clinical TrialPrincipal Investigator · Awarded by COUR Pharmaceuticals Development Co., Inc. · 2025 - 2034Endocrinology and Metabolism Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029View All Grants
Education
University of Virginia ·
1993
M.D.